dissociation one phase exponential decay algorithm prism10.2.1 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
dissociation one phase exponential decay algorithm prism10.2.1
Dissociation One Phase Exponential Decay Algorithm Prism10.2.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dissociation%E2%80%9Cone-phase+exponential+decay+algorithm/prism+10/pm39937529-524-13-14
Average 90 stars, based on 1 article reviews
Dissociation One Phase Exponential Decay Algorithm Prism10.2.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dissociation%E2%80%9Cone-phase+exponential+decay+algorithm/prism+10/pm39937529-524-13-14
Average 90 stars, based on 1 article reviews
dissociation one phase exponential decay algorithm prism10.2.1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2. Article Snippet: Fluorescently labeled ligands are versatile molecular tools to study G protein-coupled receptors (GPCRs) and can be used for a range of different applications, including bioluminescence resonance energy transfer (BRET) assays.. Here, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric binding site (IABS) of the CC chemokine receptor 2 (CCR2), a class A GPCR that has been pursued as a drug target in oncology and inflammation.. Starting from previously reported intracellular CCR2 antagonists, several tetramethylrhodamine (TAMRA)-labeled CCR2 ligands were designed, synthesized, and tested for their suitability as fluorescent reporters to probe binding to the IABS of CCR2. |